Adaptive-like CAR-iPSC-CD4⁺ T cells outperform CD8⁺ counterparts in sustained ALL control
Although not identical to primary CD4⁺ T cells, iPSC-derived CD4⁺ T cells recapitulated key functional advantages, especially sustained antitumor activity, supporting their value as a renewable, off-the-shelf source for next-generation CAR-T therapies.
Authors
- Shin Kaneko
- Chaoqi Zhang (ORCID: https://orcid.org/0009-0002-5903-3969)
- Tomoko Ishii
- Shoichi Iriguchi
- Akihiro Ishikawa
- Yohei Kawai (ORCID: https://orcid.org/0000-0002-7030-1541)
- Qisen Guo (ORCID: https://orcid.org/0009-0007-7054-5195)
- Bo Wang
- Atsutaka Minagawa
Institutions
- Kaneka (United States) (US)
- University of Tsukuba (JP)
- Kyoto University (JP)
- Kyoto Municipal Junior College of Nursing (JP)
Publication Details
- Journal
- Inflammation and Regeneration
- Published
- 2026-01-03
- DOI
- https://doi.org/10.1186/s41232-025-00402-4
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00